Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 3/20 | 0.53 |
| ▸ | MAOB | P27338 | 2/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7397155 | 0.82 | SCN9A (0.62) | SCN9AMAOBMAOAHRH3HRH1 | |
| SCHEMBL7397159 | 0.82 | SCN9A (0.62) | SCN9AMAOBMAOAHRH3HRH1 | |
| SCHEMBL4816702 | 0.81 | SCN9A (0.61) | SCN9AMAOBMAOAHRH3HRH1 | |
| SCHEMBL7397015 | 0.81 | SCN9A (0.61) | SCN9AMAOBMAOAHRH3HRH1 | |
| SCHEMBL9201087 | 0.78 | MAOA (0.62) | SCN9AMAOBMAOAHRH3HRH1 | |
| SCHEMBL8804579 | 0.78 | MAOA (0.62) | SCN9AMAOBMAOAHRH3HRH1 | |
| Hydrochloric Acid SCHEMBL5967428 | 0.76 | MAOA (0.61) | SCN9AMAOBMAOAHRH3HRH1 | |
| SCHEMBL17666275 | 0.74 | MAOA (0.65) | SCN9AMAOBMAOAHRH3HRH1 | |
| SCHEMBL1790979 | 0.74 | SCN9A (0.57) | SCN9AMAOBMAOAL3MBTL1 | |
| SCHEMBL411692 | 0.74 | SCN9A (0.57) | SCN9AMAOBMAOAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2977046-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | Newron Pharmaceuticals S.p.A. (IT) | 2016-01-27 | — | — | EP | claimed |
| US-8741957-B2 | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2014-06-03 | — | — | US | claimed |
| US-8697738-B2 | Alpha-aminoamide derivatives useful in the treatment of addictive disorders | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2014-04-15 | — | — | US | claimed |
| US-20130217747-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF RESTLESS LEGS SYNDROME | NEWRON PHARM SPA (US) | 2013-08-22 | — | — | US | claimed |
| EP-2343064-A1 | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders | Newron Pharmaceuticals S.p.A. (IT) | 2011-07-13 | — | — | EP | claimed |
| EP-1900362-B1 | Alfa-aminoamide derivatives useful in the treatment of addictive disorders | NEWRON PHARM SPA (IT) | 2011-01-12 | — | — | EP | claimed |
| CN-1942179-B | Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders | NEWRON PHARM SPA | 2010-08-11 | — | — | CN | claimed |
| EP-1658062-B1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS | NEWRON PHARM SPA (IT) | 2010-02-17 | — | — | EP | claimed |
| US-20100016437-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-01-21 | — | — | US | claimed |
| US-20100016440-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-01-21 | — | — | US | claimed |
| CN-1956714-A | Alpha-aminoamide derivatives for the treatment of lower urinary tract disorders | NEWRON PHARM SPA (IT) | 2007-05-02 | — | — | CN | claimed |
| CN-1942179-A | Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders | NEWRON PHARM SPA (IT) | 2007-04-04 | — | — | CN | claimed |
| EP-1737438-A1 | alpha-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF RESTLESS LEGS SYNDROME AND ADDICTIVE DISORDERS | Newron Pharmaceuticals S.p.A. (IT) | 2007-01-03 | — | — | EP | claimed |
| EP-1658062-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS | Newron Pharmaceuticals S.p.A. (IT) | 2006-05-24 | — | — | EP | claimed |
| WO-2005102300-A1 | α-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF RESTLESS LEGS SYNDROME AND ADDICTIVE DISORDERS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2005-11-03 | — | — | WO | claimed |
| EP-1588704-A1 | Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders | Newron Pharmaceuticals S.p.A. (IT) | 2005-10-26 | — | — | EP | claimed |
| WO-2005070405-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF LOWER URINARY TRACT DISORDERS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2005-08-04 | — | — | WO | claimed |
| EP-1557166-A1 | Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders | Newron Pharmaceuticals S.p.A. (IT) | 2005-07-27 | — | — | EP | claimed |
| WO-2005018627-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS | NEWRON PHARMACEUTICALS, SPA (IT) | 2005-03-03 | — | — | WO | claimed |
| EP-1045830-B1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANALGESIC AGENTS | NEWRON PHARM SPA (IT) | 2003-04-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016437-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | PSEN1, MAPT, AADAT | SCN9A 3223/4885MAOB 709/4885MAOA 506/4885 |
| US-20100016440-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS | IL1A, AADAT, DNPEP | SCN9A 2253/4885MAOB 1206/4885MAOA 525/4885 |
| US-20130217747-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF RESTLESS LEGS SYNDROME | AADAT, PNMT, BCAT2 | SCN9A 946/4885MAOB 53/4885MAOA 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.